LMO2 as a Biomarker for Hypersensitivity to Genotoxic Therapy

Cancer Cell. 2019 Sep 16;36(3):211-212. doi: 10.1016/j.ccell.2019.08.011.


In this issue of Cancer Cell, Parvin and colleagues identify the expression of LMO2 as a biomarker for DNA repair defects in lymphomas. Using isogenic cell lines and xenografts, the authors show that expression of LMO2 predicts sensitivity to PARP inhibition, especially in combination with genotoxic therapy.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Adaptor Proteins, Signal Transducing
  • DNA Damage
  • LIM Domain Proteins*
  • Poly(ADP-ribose) Polymerase Inhibitors*
  • Proto-Oncogene Proteins / genetics
  • Synthetic Lethal Mutations


  • Adaptor Proteins, Signal Transducing
  • LIM Domain Proteins
  • Poly(ADP-ribose) Polymerase Inhibitors
  • Proto-Oncogene Proteins